# Product Milestones

## Summary

The current milestone story should be framed around platform breadth, operational maturity, and documentation-governance improvements rather than older promotional claims.

## What Exists Now

Current repo-validated platform scope includes:

- patient and clinical service families
- quality, care-gap, and CQL execution services
- interoperability and ingestion services
- analytics and workflow services
- gateway and platform administration services
- shared security, persistence, audit, tracing, and API-contract modules

## Important Recent Milestones

### Curated investor package refresh

A newer investor/prospective-company package now separates public-safe materials from NDA-protected diligence materials.

### Platform 360 contract review

A full 360 review now exists for:

- UI-to-API contracts
- API-to-data-model contracts
- data model documentation quality

### Wave 1 contract cleanup

The first implementation wave delivered:

- truthful contract publication baseline
- patient-service route-family normalization
- shared contract and shared infrastructure documentation upgrades
- docs-to-artifact validation gates

### Atlas Nexus v2 operator surface

The cloud operator-evidence tier shipped its v2 services: an operator inbox that consumes a signed, operator-safe evidence outbox; a syndromic-surveillance service producing weekly z-scored signal buckets and outbreak indicators; and care-gap closure handoff that pseudonymizes and applies a small-cell floor (k ≥ 10) before any aggregate leaves the customer boundary.

### DQM integration

Data Quality Monitor integration is wired end-to-end: five-dimension feed scoring, HMAC-signed webhook delivery into the Atlas Nexus inbox, and an operator-safe outbox so only de-identified aggregates cross outward. This establishes the "land with feed quality" entry wedge.

## Why These Milestones Matter

These are not cosmetic documentation updates. They improve how the platform can be explained, verified, and diligenced by an external technical or investor audience.

## Related Reading

- [DEVELOPMENT-VELOCITY.md](DEVELOPMENT-VELOCITY.md)
- [PRODUCTION-READINESS.md](PRODUCTION-READINESS.md)
- [../platform/PLATFORM-OVERVIEW.md](../platform/PLATFORM-OVERVIEW.md)
